May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Moxifloxacin Ophthalmic Solution 0.5% Hastens Cure and Eradicates the Causative Pathogens of Bacterial Conjunctivitis in Pediatric and Adult Patients
Author Affiliations & Notes
  • H.R. Katz
    Ophthalmology, Krieger Eye Institute, Baltimore, MD, United States
  • W. Andrews
    Pediatric & Adolescent Medicine, Marietta, GA, United States
  • D. Creager
    U.S. Healthworks, Salt Lake City, UT, United States
  • J. De Leon
    Center for Clinical Trials, Paramount, CA, United States
  • K. Merkley
    ICON Laser Center, Midvale, UT, United States
  • L. Gower
    Alcon Research, Ltd., Fort Worth, TX, United States
  • D.W. Stroman
    Alcon Research, Ltd., Fort Worth, TX, United States
  • N. Nicholson
    Alcon Research, Ltd., Fort Worth, TX, United States
  • S. Potts
    Alcon Research, Ltd., Fort Worth, TX, United States
  • Moxifloxacin Study Group
    Alcon Research, Ltd., Fort Worth, TX, United States
  • Footnotes
    Commercial Relationships  H.R. Katz, Alcon C; W. Andrews, Alcon F, C; D. Creager, Alcon F, C; J. De Leon, Alcon F, C; K. Merkley, Alcon F, C; L. Gower, Alcon E; D.W. Stroman, Alcon E; N. Nicholson, Alcon E; S. Potts, Alcon E.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 2114. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.R. Katz, W. Andrews, D. Creager, J. De Leon, K. Merkley, L. Gower, D.W. Stroman, N. Nicholson, S. Potts, Moxifloxacin Study Group; Moxifloxacin Ophthalmic Solution 0.5% Hastens Cure and Eradicates the Causative Pathogens of Bacterial Conjunctivitis in Pediatric and Adult Patients . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2114.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the safety and efficacy of Moxifloxacin Ophthalmic Solution 0.5% [Moxi 0.5%] compared to Placebo in pediatric and adult patients with bacterial conjunctivitis. Methods: Five hundred forty-four patients, older than one month, with presumptive bacterial conjunctivitis were dosed three times daily [TID] for 4 days with either Moxi 0.5% or Placebo in a 9-day, multicenter, double-masked, prospective study. The primary clinical efficacy variable was the clinical cure rate of the two cardinal ocular signs of bacterial conjunctival infection, bulbar conjunctival injection and conjunctival discharge/exudate. Clinical cure was attained when the ratings of the two cardinal ocular signs were zero (i.e. normal or absent) approximately 5 days after the last dose, at the Day 9 test-of-cure (TOC) visit. Microbiological efficacy was bacterial eradication at the Day 9 TOC. Results: The results demonstrated that Moxi 0.5% was better than Placebo for microbiological success (82% vs. 67%; p=0.0069) and clinical cure (83% vs 74%; p=0.0991). Additionally, Moxi 0.5% was significantly more effective than Placebo for early cure at Day 3 (27% vs. 15%; p=0.0186) and at Day 5 (66% vs. 51%; p=0.0096). Prominent organisms eradicated by Moxi 0.5% were Staphylococcus epidermidis, Streptococcus pneumoniae, Staphylococcus aureus, other viridans Streptococcus, Haemophilus influenzae as well as strains resistant to earlier quinolones. Conclusions: Moxifloxacin 0.5% is effective in treating bacterial conjunctivitis. This effect is most evident by the early cures at Days 3 and 5. The results of the safety evaluation indicate that Moxifloxacin Ophthalmic Solution 0.5% is safe and well tolerated in patients older than one month when administered TID for 4 days.

Keywords: antibiotics/antifungals/antiparasitics • conjunctivitis • microbial pathogenesis: clinical studies 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×